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Protocol
AbstrACt
Introduction Advances in ST-segment elevation 
myocardial infarction (STEMI) management have involved 
improving the clinical processes connecting patients 
with timely emergency cardiovascular care. Screening 
upon emergency department (ED) arrival for an early 
ECG to diagnose STEMI, however, is not optimal for all 
patients. In addition, the degree to which timely screening 
and diagnosis are associated with improved time to 
intervention and postpercutaneous coronary intervention 
outcomes, under more contemporary practice conditions, 
is not known.
Methods We present the methods for a retrospective 
multicentre cohort study anticipated to include 1220 
patients across seven EDs to (1) evaluate the relationship 
between timely screening and diagnosis with treatment 
and postintervention clinical outcomes; (2) introduce novel 
measures for cross-facility performance comparisons 
of screening and diagnostic care team performance 
including: door-to-screening, door-to-diagnosis and door-
to-catheterisation laboratory arrival times and (3) describe 
the use of electronic health record data in tandem with an 
existing disease registry.
Ethics and dissemination The completion of this 
study will provide critical feedback on the quality of 
screening and diagnostic performance within the 
contemporary STEMI care pathway that can be used 
to (1) improve emergency care delivery for patients 
with STEMI presenting to the ED, (2) present novel 
metrics for the comparison of screening and diagnostic 
care and (3) inform the development of screening and 
diagnostic support tools that could be translated to other 
care environments. We will disseminate our results via 
publication and quality performance data sharing with 
each site. Institutional ethics review approval was received 
prior to study initiation.
IntroduCtIon  
We can find opportunities to improve 
ST-segment elevation myocardial infarction 
(STEMI) care by exploring the timeliness of 
screening and diagnosis. Each year, approx-
imately 258 000 patients present to an 
United States emergency departments 
(ED) with STEMI.1 Advances in STEMI care 
have involved improvements in the clinical 
processes connecting patients—experiencing 
this rapidly progressive pathophysiology—
with timely emergency care.2–10 The comple-
tion of screening upon ED arrival for an early 
ECG to diagnose STEMI, however, is not 
optimal for all patients.11–14 This is partic-
ularly the case when studying the percuta-
neous coronary intervention (PCI) centre 
affiliated ED subpopulation, where variation 
attributed to interfacility transfer is removed. 
Despite proximity to the location of inter-
vention, timely care is highly dependent on 
the pre-existing screening, diagnosis and 
treatment systems.6 11 14 Here, we present the 
methods for our multicentre investigation to 
(1) evaluate the relationship between timely 
strengths and limitations of this study
 ► This study overcomes the lack of adequate data 
within existing national registries to study ST-
segment elevation myocardial infarction (STEMI) 
screening and diagnosis.
 ► It presents a structured approach to multicentred 
retrospective data collection for a low frequency, but 
critical, emergency condition.
 ► Despite studying STEMI care in seven tertiary care 
academic facilities, study result will inform the 
STEMI screening and diagnostic practices of more 
diverse emergency departments as well as other en-
vironments with patients reporting acute symptoms 
suggestive of STEMI.
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screening and diagnosis with treatment time and clinical 
outcomes, (2) characterise generalisable screening and 
diagnostic measures that can be used for cross-facility 
performance comparisons and (3) describe the use of 
electronic health record (EHR) data in tandem with an 
existing disease registry.
Given the European Heart Association, American 
College of Cardiology and American Heart Associa-
tion recommendation to obtain an early ECG within 10 
min for patients with symptoms suggestive of STEMI,2–4 
nearly 85% of EDs have protocols to guide the screen of 
all arriving patients for the need of an early ECG.14 We 
define an early ECG as one performed upon ED arrival, 
typically well before physician evaluation, to diagnose 
STEMI in a timely fashion.14–16 Our prior work identified 
12.8% (95% CI 3.4% to 32.6%) of patients with STEMI do 
not receive a timely ECG. The resulting diagnostic delay 
led to 14–80 minutes of additional myocardial ischaemia 
time.14 Earlier treatment has been historically associ-
ated with better outcomes.2 3 The degree to which timely 
screening and diagnosis are associated with improved 
time to intervention and post-PCI outcomes, under more 
contemporary practice conditions, is not known. In addi-
tion, STEMI care pathway performance has not been 
explored in the ED population through a large multi-
centred patient cohort.
MEthods
study design
This is a multicentre retrospective cohort study designed to 
quantify the potential impact of improving ED screening 
and diagnostic care performance on timely STEMI treat-
ment and post-PCI outcomes. The results are intended to 
inform the design of a future EHR embedded algorithm 
to screen for STEMI upon ED arrival. We aim to describe 
our approach to quantifying the associations between (1) 
time to diagnosis and (2) time to treatment (PCI) between 
patients who do and do not receive an early ECG within 
10 min. We seek to understand variability in achieving 
timely PCI, hospital length of stay (LOS), subsequent 
heart failure and mortality by patient characteristics (ie, 
age, gender, race, language) and care process factors (ie, 
achieving timely screening, time of day, distance between 
ED and cath lab) through these prespecified subgroup 
analyses. We received institutional review board (IRB) 
approval from all participating facilities prior to study 
initiation. A shared IRB approval process was used for this 
National Institute of Health-funded study.
study setting
Participating sites are tertiary care centre EDs within a 
hospital designated as a PCI centre where the ED physi-
cian can activate the cardiac catheterization (cath) lab 
Table 1 Definition of time stamps and intervals in STEMI screening and diagnosis
TIME STAMP CARE INTERVAL DEFINITION
Symptom onset time Time of symptoms prior to arrival Recalled patient reported time for when symptoms 
associated with the acute STEMI encounter began.
Time zero
  Door time ED arrival time19
(primary analysis)
First recorded presence of the patient in the ED.
Screening
  First (early) ECG time Door to screening
Door-to-first-ECG time, D2E1st
(primary independent variable of interest)
ED arrival to completion of the first ECG. The first 
ECG is generally performed prior to the ED physician 
evaluation for the purpose of enabling the early 
identification of STEMI.
Diagnosis
  Diagnostic ECG time Door-to-diagnostic ECG, D2EDx
(secondary independent Variable of 
Interest)
ED arrival to completion of ECG used to activate the 
cath lab.
  Cath lab activation time Door-to-catheterisation laboratory 
activation 
ED arrival to the time when the cath lab was activated 
(Code STEMI).
Treatment
  Patient arrives in cath 
lab
Door-to-catheterisation laboratory arrival 
time, 
diagnostic team centric
(primary outcome)
ED arrival to patient arrival in the cath lab.
  Balloon time Door-to-balloon time,
Intervention team centric outcome
(primary outcome)
Time from ED arrival to time the catheterisation 
guidewire crossed the culprit coronary lesion in 
patients receiving balloon angioplasty.
Time zero, start time for emergency care. Outcomes, treatment times for patient with STEMI directed to percutaneous coronary 
intervention. Cath Lab, cardiac  catheterisation laboratory; ED, emergency department. 
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for emergency STEMI intervention (Code STEMI) with 
a single phone call.10
Process measures
Exploring STEMI process measures includes quantifying 
time intervals associated with STEMI screening and diag-
nosis. Door-to-screening (D2S) defined as the time from 
ED arrival to the completion of the first ECG (table 1). 
The time of ECG completion was selected to mark the 
end of screening because it is the only retrospective clin-
ical timestamp recorded to represent the completion of 
STEMI screening among those who screen positive. It is 
typical practice in EDs for ECGs to be taken directly to an 
emergency physician for interpretation.14–17 Door-to-di-
agnosis (D2D) is the interval from ED arrival to STEMI 
diagnosis (table 1). STEMI diagnosis is defined as the 
time when the physician activates a cardiac lab team 
for emergent PCI. As a result, we primarily measure 
the completion of diagnosis as door-to-cathlab activa-
tion (D2CLA). We found that cath lab activation time 
was rarely included in the medical record, maintained 
in an external telephone call centre database and incon-
sistently recorded. As a result, site principal investigators 
(PIs) were permitted to export cath lab activation times 
from their local database for the National Cardiovascular 
Data Registries’ (NCDR) Acute Coronary Treatment and 
Intervention Outcomes Network (ACTION) Get with the 
Guidelines Registry supported by the American College of 
Cardiology (NCDR-ACTION, table 2). We also included 
the time-to-diagnostic ECG as a secondary measure for 
diagnostic time.
These definitions are a necessary change from the tradi-
tional use of door to ECG as the starting point for STEMI 
performance measures and reflect how screening and 
diagnosis require separate metrics for appropriate diag-
nostic performance evaluation. Delayed STEMI screening 
and diagnosis are barriers to effective treatment access. 
By limiting our population to patients screened by the 
ED, we limit the variation in point-of-first-medical contact 
to those brought in by emergency medical services (EMS) 
or self-transport.
Patient and public involvement
The study research question and outcome measures were 
developed from a desire to evaluate how well ED STEMI 
screening and diagnosis are performed for individual 
patients. We seek to better understand the demographics 
and presentations of patients who may experience differ-
ential outcomes potentially associated with suboptimal 
STEMI screening. Patients, however, were not directly 
involved in the design or conduct of this study.
Inclusion/exclusion criteria
We will include all 2014–2016 ED patients with a final 
hospital diagnosis of STEMI. To reduce misclassification 
bias, STEMI will be defined by International Classifica-
tion of Disease (ICD-9) 9 codes previously validated in the 
literature and the corresponding ICD-10 diagnosis codes 
(table 3).1 Data abstractors, familiar with the electronic 
health record (EHR) of their institution, will review elec-
tronic patient charts for study data and to determine if 
the course of care is consistent with acute STEMI. Care 
is considered inconsistent with acute STEMI if at least 
two of the following apply: STEMI is not mentioned in 
the context of a diagnosis, the discharge summary does 
not include STEMI as a final diagnosis, there is no cath 
lab intervention, cath lab findings are not consistent 
with STEMI anatomy or intervention, and an alterna-
tive diagnosis is present for which care is most consistent 
(including non-STEMI, unstable angina and coronary 
vasospasm among others). It is recognised that some of 
these patients’ anatomy and physiology may generate 
ECG findings consistent with an appropriate diagnosis of 
STEMI from the ED. We opted to exclude these patients 
because the ultimate goal of STEMI screening from 
the ED is to identify patients who have STEMI and will 
benefit from emergent removal of an acute thrombus 
within a coronary artery. This would be the objective of 
a precision-oriented approach to screening ED patients 
on arrival for possible STEMI. We retained patients who 
received care in the ED but had a diagnostic ECG acquired 
Table 2 Study data permitted for import from local NCDR-
ACTION Registry databases
Study variable
NCDR-ACTION variable 
number
Birth date 2050
Sex 2060
Race 2070 (white)
2071 (black)
2073 (American Indian/
Alaskan Native)
2072 (Asian)
2074 (Native Hawaiian/
Pacific Islander)
Ethnicity 2076 (Hispanic vs non-
Hispanic)
Health insurance 3300 (private)
3301 (Medicare)
3302 (Medicaid)
3303+3304+3305+3306 
(other)
3307 (uninsured/self pay)
Cath lab activation time 3159
PCI (yes/no) 7100
ED discharge time 3222
Cath lab arrival date 7101
Cath lab arrival time 7102
*We did not permit the inclusion of any data that would be used 
for calculated time intervals, the primary outcome or risk factors/
exposures.
ACTION, Acute Coronary Treatment and Intervention Outcomes 
Network; ED, emergency department; NCDR, National 
Cardiovascular Data Registries; PCI, percutaneous coronary 
intervention.
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prior to hospital arrival. Their door-to-diagnostic ECG 
time would be negative and reflect an opportunity for an 
alternative care pathway, such as prehospital arrival cath 
lab activation. Cases inconsistent with acute STEMI are 
referred to the site PI for chart review. All excluded cases 
are shared with the Vanderbilt Emergency Care Health 
Services Research Data Coordinating Centre (HSR-DCC) 
central study PI (MYABY) for approval. Patients for exclu-
sion are flagged for exclusion by the HSR-DCC but not 
removed.
Primary outcomes
The primary outcome (table 1) is door--to-treatment, 
that is, time from ED arrival to STEMI treatment. An 
early ECG is defined per existing clinical practice guide-
lines2 3 14 as the time between ED arrival (the patient’s 
first recorded presence in the ED) to the completion 
of the first ECG in the ED intended to permit the 
early diagnosis of STEMI. ED arrival or ‘door’ time is 
defined as the patient’s first recorded presence in the 
ED.11 14 18 Our definition for time to treatment includes 
two outcome measures. The first measure is door-to-
cathlab- arrival (D2CAR), a diagnostic team-oriented 
measure (table 1). Patient cath lab arrival marks the last 
point in the STEMI care pathway the diagnostic team 
can influence. The second measure is door-to-balloon 
(D2B) time, the more traditionally used PCI treatment 
time measure (figure 1). During the study design phase, 
we found that D2B time was not consistently docu-
mented in the EHR at any of our seven hospitals. Thus, 
we modified definitions for this timestamp after consid-
ering the use of alternative data as established by the 
NCDR-ACTION Registry. The registry includes proxies 
for this outcome in a hierarchy such that D2B time can 
be measured primarily as balloon inflation time, yet the 
time the guidewire crosses the coronary lesion can be 
used when D2B time is missing.10 19
secondary outcomes
Secondary outcomes include ED length of stay (LOS), 
hospital LOS, change in cardiac ejection fraction (EF) 
after the acute STEMI and 1-year mortality. ED LOS is 
defined as the time from ED arrival to ED departure.18 
Change in EF is calculated as the difference between the 
last EF measured prior to the patients with STEMI and 
the first documented after hospital discharge. Hospital 
LOS is the time from hospital admission to hospital 
discharge. Mortality at 1 year was assessed by assigning 
one of three categories to a patient’s survival status 1 year 
after the STEMI ED visit: deceased (with date, time and 
cause noted), alive (based on evidence of contact with 
the health system via EHR documentation) and lost to 
follow-up.
risk factors
The independent variable of primary interest is time to 
screening defined as door-to-first ECG (D2E1st) (table 1). 
This is the screening (D2S) time interval measured as both 
a continuous variable and dichotomised (D2S ≤10 min 
vs D2S >10 min) per existing clinical practice guide-
lines.2 3 Additional risk factors of interest include infor-
mation often known about a patient on ED arrival which 
will be examined in exploratory analyses as adjusting vari-
ables. These include age, gender, race, primary language, 
arrival time (time of day), arrival mode (EMS, self-trans-
port or other) and chief complaint.
Table 3 STEMI International Classification of Disease Codes (ICD) for Inclusion by final hospital diagnosis
Acute myocardial infarction (AMI) diagnosis codes associated with STEMI
ICD 9 Diagnosis
Location
IC10 Diagnosis
Location410 AMI I21 STEMI and NSTEMI
410.21 AMI inferolateral wall Inferior I21.11 STEMI RCA Inferior
410.31 AMI inferoposterior wall I21.19 STEMI other coronary 
artery inferior
Inferior
410.41 AMI of other inferior wall I21.21 STEMI LCX Inferior
410.01 AMI anterolateral wall Anterior I21.01 STEMI left main Anterior
410.11 AMI other anterior wall I21.02 STEMI LAD Anterior
I21.09 STEMI other coronary 
artery anterior
Anterior
410.51 AMI other lateral wall Lateral I21.29 STEMI another sites Other specified
410.61 AMI true posterior wall 
infarction
Posterior
410.81 AMI other specified site* Other specified
410.91 AMI unspecified site Non-specified I21.3 STEMI unspecified Non-specified
*410.81 includes papillary muscle rupture.
LAD, left anterior descending artery; LCX, left circumflex artery; NSTEMI, non-ST-segment elevation myocardial infarction; RCA, right  coronary 
artery; STEMI, ST-segment elevation myocardial infarction. 
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secondary subgroup analysis
We also included patient characteristics known to increase 
the risk for STEMI and to be associated with outcome 
differences.3 14 These include symptom onset,19–21 as well 
as a history of diabetes (prediabetes was not included), 
hypertension, dyslipidaemia, tobacco use, heart failure, 
prior myocardial infarction, prior coronary artery bypass 
graft and prior PCI procedure. In defining variables, we 
balanced maximising covariate granularity with medical 
informatics best practice for data integration and data 
standardisation. For example, tobacco use status is 
recorded by NCDR as a dichotomous variable. In order 
to obtain more details, we collected these data primarily 
from the EHR. During the study design phase, we evalu-
ated the smoking history data available in each EHR and 
found the degree of tobacco exposure was variably cate-
gorised across our seven sites. We developed the following 
categories to maximise variability while standardising 
data reporting: current smoker, prior smoker but quit 
and non-smoker. Tobacco exposure fields in the shared 
database were limited to only accept one of these three 
smoking status designations for each patient.22 23
Recognising the impact of EHR user access and data 
use context,21 we only include information available to 
the diagnostic care providers at the time of the initial 
encounter. These providers are typically the ED team but 
can include an interventional cardiology consultant for 
rare presentations or complex patients. The NCDR-AC-
TION Registry permits the inclusion of all data available 
on review of the full medical record. The structure of the 
ED interface with EHRs varies between hospitals with 
some having more or less data available on patient arrival. 
As a result, we opted for data collection directly from the 
EHR using what is accessible during the early phases of 
the diagnostic clinical encounter.
sample size
We estimate our analysis will require 1220 patients from 
our seven study sites. This was based on our plan for a 
non-parametric Wilcoxon rank-sum test comparing 
D2B time between dichotomised door-to-first-ECG 
(D2E) groups of patients with STEMI: early ECG (D2E 
≤10 minutes) vs. missed screening (D2E >10 minutes). An 
aggregation of ICD 9/10 code counts within each hospital 
Figure 1 STEMI patient care process measures: Screening, Diagnosis and Treatment D2E1st=door-to-first ECG=door-to-early 
ECG=door to screening (D2S). D2E=door-to-diagnostic ECG=one of two ways to measure door to diagnosis (D2D). More ideally, 
D2D can be measured as door-to-catheterisation laboratory activation (D2CLA). Prehospital ECGs interpreted by the paramedic 
team as a STEMI would be represented as ‘negative’ door-to-diagnostic ECG time. These patients would ideally bypass the ED 
care pathway in the absence of an over-riding need for non-PCI (or pre-PCI) care (ie, motor vehicle collision injuries requiring 
stabilisation, witnessed cardiac arrest after prehospital ECG acquisition, etc). Thus, negative D2S would indicate potential 
opportunity for an alternative care pathway.
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from a prior studies suggests approximately 444 ED 
patients with STEMI are seen in these seven EDs annually 
with 87.2% captured with a timely early ECG and 12.8% 
in the missed screening cases.14 24 This is the effective 
sample size required to detect a standardised difference 
of 0.35, with a type I error rate of 0.05 and power of 80% 
in two-tailed tests. This is a small to medium effect size by 
Cohen’s nomenclature.25 This translates to 596 patients 
and a detectable D2B time difference of 5.2 min.26 Due 
to potential correlation in D2B between patients seen at 
the same ED, we calculated a cluster design effect of 1.84 
assuming an intercluster correlation coefficient of 0.01. 
This required us to include a minimum of 1220 patients. 
With an anticipated ICD coding misclassification exclu-
sion rate of 5%–10%, this patient sample size is achiev-
able with 3 years of data.
data collection
Cohort data for patients meeting study year, ED care and 
ICD diagnosis code inclusion criteria are extracted from 
each hospital’s EHR using a preprogrammed report to 
identify the study cohort. These data are sent securely 
to the HSR-DCC using the HIPPA and research data 
security ‘Sendit’ function of Research Electronic Data 
Capitulation (REDCap). REDCap is a secure, web-based 
application designed exclusively to support data capture 
for research studies.27–29 The cohort data for each site are 
uploaded into a subsection of the larger study database 
built and maintained by the HSR-DCC. The coordinating 
study PI and HSR-DCC staff have access to all study data, 
but individual sites only see their patient records. The use 
of a centrally designed database with built-in variable defi-
nitions and quality control checks ensured data harmoni-
sation across sites.27 30
At a minimum, cohort data include a patient iden-
tifier (typically the medical record number), ED date 
of service and final hospital ICD diagnosis codes. Each 
patient record is reviewed by a data abstractor associated 
with each institution’s ED. A REDCap-based data collec-
tion form is completed with existing EHR data that, as 
noted above, reflect information  available to diagnostic 
providers in the ED during the clinical encounter. Prior 
to data collection, each site PI completed a training case 
form (TCF, box 1) in which data were collected for the 
first patient of record for study inclusion. The location 
of each variable within the EHR, including the location 
within specific documents, was recorded and used as a 
guide for the local data abstractors. The resultant data 
dictionary was used to verify data definitions were stan-
dardised across sites. In total, we had 11 data abstractors 
from the 7 EDs. All data abstractors received a minimum 
of 2 hours of training to further ensure standardised data 
collection. Training was via a two-part module developed 
and delivered by the HSR-DCC. Part 1 involved a 90 min 
session via video conference introducing the study design, 
the data abstractors’ role in the project, study data defini-
tion and practice using all fields of the study database for 
the TCF patient. Part 2 involved repeating the data entry 
process for the TCF patient with direct use of the associ-
ated EHR record (figure 2).
We verified that all participating ED sites submit data 
for patients with STEMI to the NCDR-ACTION Registry. 
Despite the presence of this existing data registry, we under-
took primary data collection for additional information 
on ED-level STEMI care variables. Site PIs, however, were 
permitted to send select variables with identical data defi-
nitions to HSR-DCC data from their local NCDR-ACTION 
Registry database (table 2). These data were uploaded 
directly into the database by the HSR-DCC to reduced data 
entry time, and verified by data abstractors on chart review.
The data collection form within the study database 
has alerts for values outside of the expected range and 
instructions for uniform units of measure. The HSR-DCC 
staff review all completed entries for accuracy with the use 
of data cleaning checks run via R-statistical code (www. 
r- project. org, available at http:// biostat. mc. vanderbilt. 
edu/ wiki/ Main/ JenkinsEMCode) on data contained in 
the study database after the completion of 2014 data, 2015 
data and study close. The data cleaning code identifies 
box 1 data abstractor training module
 ► Part 1: 90 min video conference
 ► Content
 – Clinical problem: What is known and unknown about STEMI and 
STEMI patient outcomes
 – Study questions
 – Study design
 – Clinical care pathway for STEMI care:
 – Case study: Beverly Hospital, Beverly, Massachusetts
 – https://www.youtube.com/watch?v=FkeH036oigo  (View to 
3 min and 50 s)
 – Role of the ECG
 – PCI procedure:
 – Clinical timestamps and care documentation in the EHR
 – The procedure: PCI care and timestamps:
 – https://www.youtube.com/watch?v=I45kJJoCa6s:  (View full 
video)
 – https://www.youtube.com/watch?v=-BuazAhs7uA:  (View to 
1 min and 10 s).
 – Outcome measure data definitions (similarities and differences 
with NCDR-Get with the Guidelines ACTION Registry
 – Study procedures and timeline
 – Introduction to study database
 – Data entry with Training Case Form (TCF) example
 ► Part 2: Independent data abstraction for TCF patient directly form 
the local EHR (30 min)
 ► A Data Abstractor is approved to start data entry after Emergency 
Care Health Services Research Data Coordinating Center staff re-
view and confirm accurate and complete TCF data entry within the 
database for the TCF patient. Once confirmed, the site PI co-signs a 
delegation of authority form certifying the Data Abstractor is trained 
and will collect data under their guidance.
ACTION, Acute Coronary Treatment and Intervention Outcomes Network; EHR, 
electronic health record; NCDR, National Cardiovascular Data Registries; PCI, 
percutaneous coronary intervention; PI, principal investigator; STEMI, ST-
segment elevation myocardial infarction.
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Figure 2 Study variables not available in the NCDR-ACTION Registry. ACTION, Acute Coronary Treatment and Intervention 
Outcomes Network; ED, emergency department; EF, ejection fraction; ICD, International Classification of Disease; NCDR, 
National Cardiovascular Data Registries; PCI, percutaneous coronary intervention.
8 Yiadom MYAB, et al. BMJ Open 2018;8:e022453. doi:10.1136/bmjopen-2018-022453
Open Access 
missing values, patterns of missingness and inconsistent 
data entries (eg, an ED arrival date that occurs before 
date of birth is likely a data entry error in the year for the 
ED visit or birth). Results of the first data cleaning checks 
are communicated to the site PI and data abstractors at 
the end of 2014 data collection, discussed via telephone 
conference call, with a response verified by the HSR-DCC 
staff. Subsequent data checks are run upon request and 
at a minimum of every 30 days. Results for follow-up data 
checks are run for each site, then communicated to each 
collaborating team via email. The full report is then saved 
on a shared secure drive ( vanderbilt. box. com) managed 
by the HSR-DCC with specific subfolders for each site. 
Access permissions are set such that data for each site are 
only seen by the site PI and local data abstractors. Site 
PIs are asked to clarify ambiguous entries. The HSR-DCC 
study coordinator follows up on all requests for data 
clarification.
data analysis
Descriptive statistics for screening, diagnosis and treat-
ment time intervals including D2S (door-to-screening), 
D2D (door-to-diagnosis), D2CLA (door-to-diagnosis 
communication via cath lab activation), D2CAR (door-
to-ED-to-cardiology care transition), D2B (door-to-treat-
ment) and patient characteristics, will be calculated 
using mean, SDs and quartiles for continuous variables 
and proportions for categorical variables. They will be 
compared between the two primary exposure patient 
with STEMI groups: early ECG and missed screening 
cases using non-parametric Wilcoxon rank-sum test for 
continuous variables and χ2 test for categorical variables.
For the primary adjusted analysis, we will first use a 
linear mixed-effects regression model with D2B, as the 
outcome. The primary independent variable of interest 
is D2S status (D2E1st ≤10 min vs D2E1st >10 min) with a 
random effect for the ED providing care. We will adjust 
for ED screening methods (eg, point of first patient 
contact in the ED, dedicated space for early ECGs, etc), 
care process factors (eg, time of day, distance between ED 
and cath lab, etc) and individual patient characteristics. 
Since D2S is a portion of D2B, we will use the first-ECG-
to-balloon time interval26 calculated by subtracting D2S 
from D2B as the primary outcome in this model. Results 
from those adjusted analyses will help quantify differences 
in timely care between early ECG and missed screening 
case patients with STEMI and reduction in door-to-treat-
ment (D2B) for every minute saving in time to screening 
(D2E). These analyses will be repeated with D2CAR as 
the outcome, then D2D as the independent variable of 
interest.31
We will then perform a time-to-event analysis using 
the Cox proportional hazard model stratified by ED for 
each secondary outcome event (hospital LOS and 1-year 
mortality), and a linear mixed-effects regression model 
with ED random effect for continuous outcomes (change 
in cardiac EF after acute STEMI) with the same adjust-
ments and independent variables as the primary analysis.
Lastly, we will use our adjusted data to construct a 
summary of the care course (the sequence of median 
STEMI process intervals) by age, gender, race, language, 
presenting symptom and ED subgroups to identify differ-
ences in the following time intervals: symptom-onset-to-ar-
rival, arrival-to-first ECG, first-ECG-to-diagnostic-ECG, 
diagnostic-ECG-to-cathlab-activation, activation-to-PCI 
balloon, PCI-to-hospital discharge (see figure 1).
dIsCussIon
Despite the limitations of retrospective EHR data, we 
selected this approach over a prospective study for 
several reasons. First, the time and financial cost of the 
prospective approach would make the study impracti-
cable. Prospective enrolment would require 4 years to 
complete data collection and continued screening of 
ED patients. The cost would outweigh the enrolment 
yield given the relative infrequency of STEMI events 
within the larger ED patient population. These logistics 
would significantly slow our ability to generate knowl-
edge to inform an important study question for a deadly 
disease. Second, our targeted screening intervention 
will use EHR data available to the ED care team on 
arrival, therefore, the use of existing EHR data will be 
subject to similar data conditions during intervention 
implementation.
Substantial resources are allocated to assure screening 
and diagnosis within 10 minutes of patient arrival 
to achieve timely STEMI treatment. Yet no existing 
measures or databases have adequate granularity to 
measure screening and diagnostic practice or to guide 
performance optimisation. Much of the resource invest-
ment reflects the major consequences and medicolegal 
gravity of a missed STEMI in the context of time limited 
interventions, high mortality and significant morbidity. 
If interventions are to be developed to more precisely 
identify patients with STEMI on ED arrival, data on ED 
patients with STEMI are critical. These interventions 
need to be balanced with appropriate use of resources 
for this infrequent but potentially deadly condition.
Current practices are often supported by data 
extrapolated from the more broad population of 
hospital STEMI patients who may be different from 
the ED subpopulation. This study will increase our 
understanding of whether those missed by ED STEMI 
screening receive less timely interventional care (PCI) 
than those with timely STEMI screening and diagnosis. 
It will better characterise the care process, demographic 
profile and clinical outcomes for this subpopulation of 
patients with STEMI. The primary results of this study 
will be a comparison of differences in the timeliness of 
treatment between those who experienced timely versus 
delayed screening and diagnosis. Our subgroup analysis 
may identify risk factors for poor outcomes providing 
data to focus clinical interventions to deliver precise 
diagnostic care normalised for subgroup-specific risk 
factors.
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The American Heart Association recently called for 
growth in the use of linked registry and EHR data to 
understand the penetration of cardiovascular care 
guidelines and evidence within clinical practice.32 Our 
methods present an applied approach to the use of 
EHR data for emergency care sensitive cardiovascular 
disease diagnoses. NCDR-ACTION Registry is a robust 
risk-adjusted, outcomes-based, quality improvement 
programme that focuses exclusively on patients with 
high-risk STEMI and non-NSTEMI. The registry data-
base has revolutionised our ability to study outcomes 
for these high-risk conditions despite their relatively low 
prevalence at any given centre. However, the NCDR-AC-
TION Registry is focused on treatment performance, 
and it lacks variables (figure 2) to support evidence-
based screening and diagnostic performance evalu-
ation to improve clinical practice. In contemporary 
practice the existence of EHRs is more the norm than 
the exception.33 EHRs provide a vehicle for source data 
and the potential application of dynamic clinical deci-
sion support to enhance risk stratification and mecha-
nisms for evidence-based care delivery. In this study, we 
used standardised multicentre primary data collection 
from seven hospital EHRs to enable our ability to study 
these early STEMI care performance targets.
The completion of this study will provide a more accu-
rate appraisal and critical feedback on the quality of 
contemporary STEMI care pathway performance that 
can be used to improve emergency care delivery for ED 
patients with STEMI, and inform the development of 
screening and diagnostic support tools that can be trans-
lated to other care environments. Specifically, we will 
better understand the consequences of and risk factors 
for delayed screening and diagnosis. We anticipate our 
results will be extrapolated to other care delivery spaces 
that receive undifferentiated patients (non-PCI centre 
EDs and urgent care). What is learnt about differential risk 
may be applied in primary care clinics, intake processes 
for direct to floor admissions and interservice floor trans-
fers. Tools developed to improve screening may be used 
for other emergency care sensitive conditions.
EthICs dIssEMInAtIon
Manuscript publication is our primary plan for results 
dissemination. Given the critical nature of STEMI, we 
plan to simultaneously share our study results with the 
participating institutions STEMI care quality improve-
ment committees, Divisions of Cardiology as well as ED 
leadership. The study data will be available to other 
researchers on a case-by-case basis via the Vanderbilt 
University Emergency Care Health Services Research 
Data Coordinating Center (HSR-DCC). Statistical code 
will be made available on the HSR-DCC website.
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